Methods of treating high risk multiple myeloma

1. A method of achieving negative minimal residual disease status in a subject having high-risk multiple myeloma, comprising administering to the subject an anti-CD38 antibody, dexamethasone, and bortezomib, wherein:

the anti-CD38 antibody comprises a heavy chain complementarity determining region (HCDR) 1, a HCDR2, a HCDR3, a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 amino acid sequences of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively; wherein:

the anti-CD38 antibody is administered as an intravenous infusion at a dose of about 16 mg/kg once per week in a 21-day cycle on days 1, 8, and 15 for cycles 1-3, once every 3 weeks in a 21-day cycle on day 1 for cycles 4-8, and once every 4 weeks thereafter; and

bortezomib is administered at a dose of about 1.3 mg/m 2 subcutaneously (SC) in a 21-day cycle on days 1, 4, 8, and 11 for cycles 1-8; and

dexamethasone is administered at 20 mg IV or PO in a 21-day cycle on days 1, 2, 4, 5, 8, 9, 11, and 12 for a total dose of 160 mg per cycle for cycles 1-8, wherein:

the subject has one or more chromosomal abnormalities comprising:

a) t(4;14)(p16;q32);

b) t(14;16)(q32;q23);

c) t(4;14)(p16;q32) and t(14;16)(q32;q23);

d) t(4;14)(p16;q32) and del17p;

e) t(14;16)(q32;q23) and del17p; or

f) t(4;14)(p16;q32), t(14;16)(q32;q23) and del17p; and

wherein the method increases progression-free survival events compared to administering dexamethasone and bortezomib without the anti-CD38 antibody.

2. The method of claim 1 , wherein the subject has relapsed or refractory multiple myeloma.

3. The method of claim 1 , wherein the anti-CD38 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5.

4. The method of claim 1 , wherein the anti-CD38 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 12 and a light chain comprising the amino acid sequence of SEQ ID NO: 13.

5. The method of claim 1 , wherein the negative minimal residual disease is detected by evaluating an amount of myeloma cells in a bone marrow aspirate sample from the subject.

6. A method of decreasing a risk of relapse and/or disease progression in a subject having high-risk multiple myeloma, comprising administering to the subject an anti-CD38 antibody, dexamethasone, and bortezomib, wherein:

the anti-CD38 antibody comprises a heavy chain complementarity determining region (HCDR) 1, a HCDR2, a HCDR3, a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 amino acid sequences of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively; wherein:

the anti-CD38 antibody is administered as an intravenous infusion at a dose of about 16 mg/kg once per week in a 21-day cycle on days 1, 8, and 15 for cycles 1-3, once every 3 weeks in a 21-day cycle on day 1 for cycles 4-8, and once every 4 weeks thereafter; and

bortezomib is administered at a dose of about 1.3 mg/m 2 subcutaneously (SC) in a 21-day cycle on days 1, 4, 8, and 11 for cycles 1-8; and

dexamethasone is administered at 20 mg IV or PO in a 21-day cycle on days 1, 2, 4, 5, 8, 9, 11, and 12 for a total dose of 160 mg per cycle for cycles 1-8, wherein:

the subject has one or more chromosomal abnormalities comprising:

a) t(4;14)(p16;q32);

b) t(14;16)(q32;q23);

c) t(4;14)(p16;q32) and t(14;16)(q32;q23);

d) t(4;14)(p16;q32) and del17p;

e) t(14;16)(q32;q23) and del17p; or

f) t(4;14)(p16;q32), t(14;16)(q32;q23) and del17p; and

wherein the method increases progression-free survival events compared to administering dexamethasone and bortezomib without the anti-CD38 antibody.

7. A method of treating a subject having high-risk multiple myeloma, comprising administering to the subject an anti-CD38 antibody, dexamethasone, and bortezomib, wherein:

the anti-CD38 antibody comprises a heavy chain complementarity determining region (HCDR) 1, a HCDR2, a HCDR3, a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 amino acid sequences of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively; wherein:

the anti-CD38 antibody is administered as an intravenous infusion at a dose of about 16 mg/kg once per week in a 21-day cycle on days 1, 8, and 15 for cycles 1-3, once every 3 weeks in a 21-day cycle on day 1 for cycles 4-8, and once every 4 weeks thereafter; and

bortezomib is administered at a dose of about 1.3 mg/m 2 subcutaneously (SC) in a 21-day cycle on days 1, 4, 8, and 11 for cycles 1-8; and

dexamethasone is administered at 20 mg IV or PO in a 21-day cycle on days 1, 2, 4, 5, 8, 9, 11, and 12 for a total dose of 160 mg per cycle for cycles 1-8, wherein:

the subject has one or more chromosomal abnormalities comprising:

a) t(4;14)(p16;q32);

b) t(14;16)(q32;q23);

c) t(4;14)(p16;q32) and t(14;16)(q32;q23);

d) t(4;14)(p16;q32) and del17p;

e) t(14;16)(q32;q23) and del17p; or

f) t(4;14)(p16;q32), t(14;16)(q32;q23) and del17p; and

wherein the method increases progression-free survival events compared to administering dexamethasone and bortezomib without the anti-CD38 antibody.

8. The method of claim 7 , wherein the anti-CD38 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5.

9. The method of claim 7 , wherein the anti-CD38 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 12 and a light chain comprising the amino acid sequence of SEQ ID NO: 13.

10. The method of claim 7 , wherein the subject has high risk refractory or relapsed multiple myeloma.

11. The method of claim 7 , wherein the method further improves one or more outcome measurements of the subject compared to a subject receiving dexamethasone and bortezomib.

12. The method of claim 7 , wherein the method achieves minimal residual disease-negativity in the subject.